Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

L. Zlamalikova, M. Moulis, B. Ravcukova, K. Liskova, J. Malcikova, D. Salek, J. Jarkovsky, M. Svitakova, R. Hrabalkova, J. Smarda, J. Smardova,

. 2017 ; 38 (4) : 2535-2542. [pub] 20170808

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033784

Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033784
003      
CZ-PrNML
005      
20181015123248.0
007      
ta
008      
181008s2017 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2017.5891 $2 doi
035    __
$a (PubMed)28791403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Zlamalikova, Lenka $u Department of Pathology, University Hospital, Brno, Czech Republic.
245    10
$a Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas / $c L. Zlamalikova, M. Moulis, B. Ravcukova, K. Liskova, J. Malcikova, D. Salek, J. Jarkovsky, M. Svitakova, R. Hrabalkova, J. Smarda, J. Smardova,
520    9_
$a Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $x patologie $7 D016403
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x genetika $x patologie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    12
$a prognóza $7 D011379
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a kvasinky $x genetika $7 D015003
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moulis, Mojmir $u Department of Pathology, University Hospital, Brno, Czech Republic.
700    1_
$a Ravcukova, Barbora $u Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic.
700    1_
$a Liskova, Kvetoslava $u Department of Pathology, University Hospital, Brno, Czech Republic.
700    1_
$a Malcikova, Jitka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Salek, David $u Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno, Czech Republic.
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Svitakova, Miluse $u Department of Pathology, University Hospital, Brno, Czech Republic.
700    1_
$a Hrabalkova, Renata $u Department of Pathology, University Hospital, Brno, Czech Republic.
700    1_
$a Smarda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Smardova, Jana $u Department of Pathology, University Hospital, Brno, Czech Republic.
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 38, č. 4 (2017), s. 2535-2542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28791403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015123744 $b ABA008
999    __
$a ok $b bmc $g 1340292 $s 1030778
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 38 $c 4 $d 2535-2542 $e 20170808 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options